Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | CRHBP | P24387 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.64 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.61 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.61 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244620 | 0.85 | EGFR (0.70) | EGFRALDH1A1MAPTHTTMEN1 | |
| SCHEMBL1192454 | 0.82 | EGFR (1.00) | EGFRALDH1A1MAPTHTTMEN1 | |
| SCHEMBL4587672 | 0.81 | ALK (0.79) | EGFRALDH1A1MAPTHTTMEN1 | |
| SCHEMBL30552991 | 0.80 | EGFR (1.00) | EGFRALKABCG2 | |
| SCHEMBL3244621 | 0.80 | EGFR (1.00) | EGFRALKABCG2 | |
| SCHEMBL28797756 | 0.79 | EGFR (0.61) | EGFRALDH1A1MAPTHTTMEN1 | |
| SCHEMBL4586679 | 0.78 | EGFR (0.70) | EGFRALDH1A1CYP1A2CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL7760844 | 0.76 | EGFR (0.60) | EGFRALDH1A1MAPTHTTMEN1 | |
| SCHEMBL3243771 | 0.76 | EGFR (0.60) | EGFRALDH1A1MAPTHTTMEN1 | |
| SCHEMBL3960657 | 0.76 | EGFR (0.67) | EGFRALDH1A1MAPTHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594504-A4 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T K SIGNAL LTD (IL) | 2008-12-17 | — | — | EP | disclosed |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | T.K. SIGNAL LTD. (IL) | 2006-02-02 | — | — | US | disclosed |
| EP-1594504-A2 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T.K. Signal Ltd. (IL) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004064718-A2 | IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF | T.K. SIGNAL LTD. (IL) | 2004-08-05 | — | — | WO | disclosed |
| EP-1039910-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | American Cyanamid Company (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999024037-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | EGFR, ERBB2, ERBB3 | EGFR 1/4885ALDH1A1 3537/4885MAPT 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.